Global $8.2 Bn Contraceptives Market Opportunity Analysis and Forecasts to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 28, 2019--The “Contraceptives: Opportunity Analysis and Forecasts to 2027” report has been added to ResearchAndMarkets.com’s offering.
Contraceptive market sales were estimated to be $6.3bn across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) in 2017, which is expected to grow to $8.2bn in 2027, at a compound annual growth rate of 2.7%.
“Contraceptives: Opportunity Analysis and Forecasts to 2027”, states that the launch of four novel contraceptive drug candidates will drive growth of the female contraceptive market over the forecast period. Launching products include Mithra’s combined pill, Estelle, Evofem’s non-hormonal gel, Amphora, The Population Council’s and Antares’ transdermal gel, Nestragel, and The Population Council’s and Therapeutics MD’s extended-release vaginal ring, Annovera (already approved in the US).
Increased contraceptive choices will raise the chance of finding suitable contraceptives for individual needs, whilst increasing contraceptive market growth in the next ten years.
The majority of contraceptives sales will come from the US, attributable to the new product launches. Japan’s sales will fall at a negative CAGR of 1.1% by 2027 as a result of a decreasing female population. China, on the other hand, will become the fourth largest contraceptive market by 2027 as a result of a growing population and growing demand for contraceptives, in spite of the lack of launch of a new contraceptive, indicating a great opportunity for foreign drug developers to enter the Chinese contraceptive market.
Presently, marketed contraceptives can cause damaging side effects and are one of the main reasons why patients may decide to discontinue contraceptive use, leading to unintended pregnancies. Therefore, the launch of the four drugs will fill important unmet needs and shape the contraceptive space.
Contraceptives in late-stage clinical development, Phase IIb and Phase III, contain novel, more natural progesterones or estrogens that are aimed at decreasing androgenic and estrogenic side effects, respectively, associated with current formulations.
An interesting product in Phase III is Evofem’s Amphora, which is a non-hormonal vaginal gel designed to maintain an acidic environment, which is inhospitable to sperm as well as certain pathogens. If it proves effective against certain investigated sexually transmitted disease (STD) prevention, its dual benefit will make this contraceptive a desirable method of contraception.
Key Questions Answered
- Combination oral contraceptives (COCs) have dominated the contraceptives market for many years. However, there has been an increased usage of other contraceptive routes of administration, such as hormonal intrauterine devices (IUDs), vaginal rings, and subcutaneous implants. What are the treatment trends during the forecast period? What factors do women take into account when choosing a contraceptive?
- There are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the contraceptives market?
- How will the entrance of the five late stage pipeline drugs affect the global contraceptive treatment landscape?
- Overview of contraceptives, including patterns of treatment, unmet needs and opportunity, current treatment landscape, pipeline drug analysis, and R&D strategies.
- Annualized contraceptives market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the contraceptives market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global contraceptives market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Contraceptives: Executive Summary
2.1 Moderate Growth in the Contraceptives Market Is Expected Between 2017 and 2027, Driven by US and China Sales
2.2 Developers Targeting Other Female Health Conditions in Addition to Contraception
2.3 The Contraceptives Market Is Still in Need of Therapeutics with Better Safety Profiles
2.4 Significant Opportunity Remains in Chinese and Japanese Contraceptives Markets
2.5 The Diverse Late-Stage Pipeline Offers Women More Options for Contraception
2.6 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.2 Other Indications
5 Current Treatment Options
6 Unmet Needs and Opportunity Assessment
6.2 Hormonal Contraceptives with Reduced Adverse Reactions
6.3 Non-hormonal Contraceptives
6.4 Better Compliance and Adherence to Contraceptives
6.5 Access to a Wide Range of Contraceptive Methods
6.6 Awareness of Different Contraceptive Methods
7 R&D Strategies
7.1.1 Development of Novel Non-hormonal Contraceptives
7.1.2 Utilization of Contraceptives for Other Disease Indications
7.1.3 New Drug Delivery Technologies
7.2 Clinical Trials Design
7.2.1 Pearl Index as an Efficacy Tool
7.2.2 Selection of an Active Comparator
8 Pipeline Assessment
8.2 Innovative Early-Stage Approaches
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top-Line 10-Year Forecast
- Agile Therapeutics
- Antares Pharma Bayer
- Exeltis Germany
- Evofem Biosciences
- Fuji Pharma Co.
- Mithra Pharmaceuticals
- The Population Council
- Sebela Pharma
- Therapeutics MD
- Viramal Ltd
For more information about this report visit https://www.researchandmarkets.com/research/2xr2hf/global_8_2_bn?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190328005647/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Women’s Health
INDUSTRY KEYWORD: WOMEN HEALTH CONSUMER GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/28/2019 11:13 AM/DISC: 03/28/2019 11:13 AM